PBI-Gordon Companies, Inc., the parent company of TriviumVet, which holds sole conditional new animal drug approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) under its affiliated brand company Pegasus, issued a cease-and-desist demand letter to Petspan for falsely promoting a compounded version of rapamycin (synonymous with sirolimus) for the treatment and management of clinical hypertrophic cardiomyopathy (HCM) in cats. Issued through its outside counsel, the order states Petspan’s evaluation and prescribing practices do not comply with established veterinary practice principles and places the health and well-being of cats in jeopardy.
Felycin®-CA1 is the only drug to receive FDA conditional approval for management of ventricular hypertrophy with subclinical hypertrophic cardiomyopathy in cats.
Source: businesswire, July 21, 2025. Link.